The drug has been reported previously to cause neuropathy and hypersensitivity reactions in breast cancer patients.

Cardiff Oncology, Inc. (NASDAQ:CRDF) announced groundbreaking Phase 1b clinical trial results for its PLK1 inhibitor ...

The addition of relacorilant to nab-paclitaxel significantly extended survival for women with platinum-resistant ovarian ...

Nearly 40% had diabetes, 17% had renal failure/impairment, and 26% had chronic limb-threatening ischemia (CLTI; Rutherford class ... that paclitaxel DCBs have progressed with each generation and have ...

With drug-coated balloons, paclitaxel’s ability to stick around in the tissue ... versus paclitaxel-coated balloon and to confirm the absence (or presence) of a class effect in DCBs.” Bernardo Cortese ...

Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...

and I believe utilization of this class of technology will continue to grow and evolve over time as the science is expanding. In a field largely reliant on paclitaxel drug-coated balloons ...

Musculoskeletal - Muscle and joint pain. Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor positive breast cancer.

Relacorilant combined with nab-paclitaxel (Abraxane) significantly improved progression-free and overall survival in patients with platinum-resistant ovarian cancer in the phase 3 ROSELLA trial, ...

Nab-paclitaxel is a chemotherapy drug. It combines the chemotherapy drug paclitaxel with a protein called albumin. It works by stopping cancer cells separating into two new cells, so it blocks the ...